Archives

  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2020-03
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • br At the distal radius total area did not

    2022-07-28


    At the distal radius, total area did not differ between groups, despite being 3.5% to 4.5% higher in ADT-treated men compared to controls. In contrast, ADT-treated men had significantly lower distal radius total vBMD (14.4% and 12.2%, both P = 0.001) and trabecular vBMD (14.8%, P = 0.003; 10.7%, P = 0.029) compared to PCa and healthy controls, respectively. BSI of the distal radius was 27.5% and 23.6% lower in ADT-treated men compared to PCa and healthy controls, re-spectively (both P < 0.001). There were no significant differences between groups for any bone structure, density or strength outcomes at the proximal radius. Similarly, there were no differences between PCa and healthy controls for any vBMD, structure or strength outcomes at the tibia or radiusFig. 2.
    Table 2
    Adjusted mean (95% CI) areal and volumetric bone mineral density (BMD), bone structure and strength in men with prostate cancer (PCa) treated with androgen deprivation therapy (ADT), PCa controls and healthy controls.
    N Healthy controls N PCa controls N ADT-treated men P-value
    Lumbar spine (g/cm2)
    pQCT
    Data Methylpiperidino pyrazole adjusted means with 95% confidence interval, and results are adjusted for BMI and tibia or radius length (for pQCT outcomes). aP < 0.05, bP < 0.01, cP < 0.001 compared to healthy controls. dP < 0.05, eP < 0.01, fP < 0.001 compared to PCa controls. #Analyses completed using natural log-transformed data. DXA, dual-energy X-ray absorptiometry; pQCT, peripheral quantitative computed tomography; vBMD, volumetric bone mineral density; BSI, bone strength index; Ipolar, density-weighted polar cross-sectional moment of inertia.
    Table 3
    Adjusted mean (95% CI) cortical bone density distribution in men with prostate cancer (PCa) treated with androgen deprivation therapy (ADT), PCa controls and healthy controls.
    N Healthy controls N PCa controls N ADT-treated men P-valuea
    Endocortical vBMD (mg/cm3)
    Endocortical vBMD (mg/cm3)
    Data are adjusted mean with 95% confidence interval, and results adjusted for BMI and tibia or radius length. vBMD, volumetric bone mineral density.
    a Analyses completed using natural log-transformed data.
    A Distal Tibia B Distal Radius
    Total Area Total Area
    Trabecular vBMD Trabecular vBMD
    mg/cm
    Bone Strength Index
    Bone Strength Index
    Healthy PCa ADT-treated controls controls men 
    Healthy PCa ADT-treated
    controls controls men
    Fig. 1. Mean ( ± standard error) pQCT-derived outcomes at distal sites of the Abundant mRNA A) tibia and B) radius in healthy controls, PCa controls and ADT-treated men, adjusted for BMI and tibia or radius length. *P < 0.05 compared to healthy controls, #P < 0.05 compared to PCa controls. vBMD, volumetric bone mineral density; PCa, prostate cancer; ADT, androgen deprivation therapy; pQCT, peripheral quantitative computed tomography.
    A Proximal Tibia B Proximal Radius
    Cortical Area Cortical Area
    Cortical vBMD
    Cortical vBMD
    Ipolar
    I
    polar
    Healthy PCa ADT-treated
    controls controls men 
    Healthy PCa ADT-treated
    controls controls men
    Fig. 2. Mean ( ± standard error) pQCT-derived outcomes at proximal sites of the A) tibia and B) radius in healthy controls, PCa controls and ADT-treated men, adjusted for BMI and tibia or radius length. vBMD, volumetric bone mineral density; I polar, density-weighted polar cross-sectional moment of inertia; PCa, prostate cancer; ADT, androgen deprivation therapy; pQCT, peripheral quantitative computed tomography. r> 3.4. Cortical bone distribution r> There were no differences between groups for average endocortical, midcortical or pericortical vBMD of either the proximal tibia or radius (Table 3). There were also no differences between PCa and healthy controls for any cortical bone distribution outcomes.